Hook & thesis
Rocket Lab just moved from a niche launch-and-small-satellite supplier to a company that can realistically pitch a full defense-oriented space stack. The close of the Mynaric acquisition and the retention of Mynaric's Munich headquarters give Rocket Lab immediate optical laser communications capability, a European footprint, and a seat at a $1.3 billion program table. That combination matters: defense customers prize integrated suppliers that can reduce procurement friction and secure supply chains.
My trade idea: take a long position in Rocket Lab at an entry of $82.935, targeting $99.58 with a stop at $68.00. The view is a long-term directional trade (180 trading days) that plays strategic M&A-led upside, program revenue recognition over the next 12-24 months, and continued positive technical momentum.
What Rocket Lab does and why the market should care
Rocket Lab operates two primary businesses: Launch Services and Space Systems. Launch Services sells dedicated and rideshare launches; Space Systems builds spacecraft components, spacecraft, and provides on-orbit operations. Historically the market has valued Rocket Lab as a launch company, but the company is deliberately expanding its product set into satellite subsystems and mission services.
The recent acquisition of Mynaric (closed in mid-April 2026) brings optical laser communications into Rocket Lab's product portfolio. That is not a trivial add-on. Optical terminals can multiply data throughput from LEO constellations and are increasingly mandated in defense architectures for secure, high-bandwidth links. Mynaric will remain headquartered in Munich, marking Rocket Lab's first tangible European presence and reducing barriers to entry for NATO and EU defense business.
Hard numbers that matter
| Metric | Value |
|---|---|
| Current Price | $82.935 |
| Market Cap | $47.22B |
| Shares Outstanding | 569,408,000 |
| Free Cash Flow (last) | -$321,806,000 |
| EPS (ttm) | -$0.34 |
| Price / Sales | 70.69x |
| Price / Book | ~24.7x |
| Cash (current) | $2.48 per share |
| 52-week High / Low | $99.58 / $18.21 |
The valuation is aggressive on surface metrics: price-to-sales near 71x and a price-to-book in the mid-20s. But this is a growth-and-technology story where the market is pricing future program revenue and platform-level margins rather than current GAAP profits. The company is projecting and planning to scale revenue - analyst commentary in the market pegs Rocket Lab's target to roughly $1.6 billion by 2028 - and management has a stated path to profitability in 2027. Those forward expectations are what justify the premium multiple for now.
Why the Mynaric acquisition changes the equation
There are three important, quantifiable effects of the Mynaric deal.
- Mynaric fills a supply-chain gap in optical terminals - the company already has a $1.3 billion contract to supply CONDOR Mk3 terminals for 36 satellites under a major defense program. That contract anchors a clear near-term revenue stream and ties Rocket Lab to program-level budgets.
- Mynaric establishes a European headquarters in Munich, which materially lowers political and procurement friction for defense contracts within NATO/EU jurisdictions versus a pure U.S.-headquartered vendor.
- The acquisition consideration was modest relative to Rocket Lab's market cap - $155.3 million in cash and stock - meaning share dilution was limited and the strategic upside is outsized if deployment scales.
Technical backdrop
Momentum is currently favorable. The 10-day SMA sits near $70.50 and the 50-day SMA near $70.17, both well under the current price of $82.935. RSI is elevated at ~65, and the MACD shows bullish momentum with a positive histogram, indicating institutional buying and trend-following flows are supportive.
Catalysts to drive the trade
- Program revenue recognition tied to the CONDOR Mk3 deliveries - as terminals ship and satellites integrate, expect incremental upside to Space Systems bookings and revenue over the next 12-24 months.
- Additional defense contracts and European procurement wins enabled by a Munich presence - governments tend to favor local industrial participation.
- Sector momentum from large events such as the SpaceX IPO and broader space financing lifting the group - momentum in mid-April 2026 has already spurred multiple peer re-ratings.
- Operational cadence: Gauss electric thruster product launches and scaled manufacturing that squeeze unit economics and improve gross margins.
Trade plan
Entry: $82.935
Target: $99.58 (reflects the 52-week high and a realistic near-term upside if program execution is validated)
Stop loss: $68.00
Horizon: long term (180 trading days). Why this length? Defense contract revenues and deliveries, integration testing, and program certifications typically play out over multiple quarters. The acquisition's benefits (cross-selling, European bids, supply continuity) are realized on a multi-quarter cadence, which argues for patience. The stop is tight enough to limit downside if momentum breaks and loose enough to avoid being stopped by near-term noise tied to program timing.
Risk framing - what could go wrong
- Execution risk on integration: integrating Mynaric's technology into Rocket Lab's sales and manufacturing processes is non-trivial. Delays or failure to meet MIL-spec requirements would delay revenue and could damage credibility with prime contractors.
- Valuation compression: current multiples assume successful top-line scaling. Any miss in revenue growth or deferred profit timelines could trigger sharp multiple contraction from current lofty levels (P/S > 70x).
- Program concentration: the $1.3 billion CONDOR Mk3 work is meaningful, but concentration risk exists. If schedule slips or contract scope is reduced, the revenue cliff could be significant.
- Capital intensity and cash burn: free cash flow is negative (roughly -$322M in the last reported window). Sustained cash burn without commensurate bookings could force dilutive financing, pressuring the share price.
- Competitive and geopolitical pressure: Space is strategically sensitive. Larger incumbents (and unique political pressures around export controls) can restrict market access or support for certain customers, especially where sovereignty and domestic sourcing are priorities.
Counterargument to the thesis
One reasonable counterargument: the market is already pricing this strategic pivot and the acquisition premium into the stock. At current multiples, Rocket Lab needs near-perfect execution to justify the valuation. If the wider space sector cools after the initial SpaceX IPO euphoria or if defense budgets favor incumbents with deeper balance sheets, RKLB could trade down significantly despite the strategic logic. This is a valid, scenario-based challenge and is part of the reason the trade uses a well-defined stop.
What would change my mind
I would materially reduce conviction if any of the following occur: a) Rocket Lab delays CONDOR Mk3 deliveries beyond one year, b) management pulls forward plans to raise equity or debt in a dilutive way, c) integration issues with Mynaric prompt a visible technology or certification failure, or d) revenue guidance is cut. Conversely, evidence of multi-contract wins in Europe, incremental margin expansion in Space Systems, or consistently improving free cash flow would strengthen the bull case and warrant raising the target.
Bottom line: Rocket Lab’s acquisition of Mynaric is a strategic pivot that adds defense-grade optical comms and a European base. The market values the company for future program wins and higher-margin systems revenue; the trade is a long that respects valuation risk with a clear stop and a multi-quarter time frame to let program economics materialize.
Key data points to watch (monitor weekly)
- Program award notices or delivery milestones tied to CONDOR Mk3.
- Quarterly updates on Space Systems bookings and backlog recognition.
- Free cash flow trajectory and any financing moves.
- Short interest and daily short volume - these can exacerbate moves in either direction during earnings or news events.
Final stance
I am long RKLB on the trade plan above. The acquisition materially improves the company's strategic positioning in defense and Europe, and the risk/reward at $82.935 with a $68 stop and $99.58 target is attractive to disciplined, patient traders who accept execution risk. If the company can translate program awards into steady revenue and demonstrate margin expansion, the stock can re-price meaningfully higher; if not, the stop protects capital.